Review



ceacam8 mab  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems ceacam8 mab
    Ceacam8 Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/Human+CEACAM-8%2FCD66b+Antibody/us12521446-1286-1-3
    Average 94 stars, based on 1 article reviews
    ceacam8 mab - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Binding Assay:

    Article Title: Anti-CEACAM5 antibody drug conjugates
    Article Snippet: .. The CEACAM5 mAbs were similarly examined for binding to human CEACAM8 (R&D Systems catalog #9639-CM-050). .. Commercial CEACAM8 mAb (R&D Systems catalog #MAB4246) showed binding to CEACAM8 but no binding was observed for the CEACAM5 mAbs (data not shown).



    Similar Products

    ceacam8 mab  (R&D Systems)
    94
    R&D Systems ceacam8 mab
    Ceacam8 Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/Human+CEACAM-8%2FCD66b+Antibody/us12521446-1286-1-3
    Average 94 stars, based on 1 article reviews
    ceacam8 mab - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    human ceacam8  (R&D Systems)
    94
    R&D Systems human ceacam8
    Human Ceacam8, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/Recombinant+Human+CEACAM-8%2FCD66b+Protein%2C+CF/us12521446-1285-9-11
    Average 94 stars, based on 1 article reviews
    human ceacam8 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ab239990 anti human cd66b g10f5 novus  (Novus Biologicals)
    94
    Novus Biologicals ab239990 anti human cd66b g10f5 novus
    Ab239990 Anti Human Cd66b G10f5 Novus, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/CEACAM8%2FCD66b+Antibody+(G10F5)/pmc11645280__41591_2024_3354_MOESM1_ESM-7-122-126
    Average 94 stars, based on 1 article reviews
    ab239990 anti human cd66b g10f5 novus - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    human ceacam8/cd66b  (MyBiosource Biotechnology)
    90
    MyBiosource Biotechnology human ceacam8/cd66b
    PGLYRP1, CAMP, MMP9, and <t>CEACAM8</t> mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.
    Human Ceacam8/Cd66b, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/human+elisa/pmc11395913-241-30-32
    Average 90 stars, based on 1 article reviews
    human ceacam8/cd66b - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    cd66b ceacam8 granulocytes apc rea306 ud 130 117 692 miltenyi biotec cd68 macrosialin  (Miltenyi Biotec)
    94
    Miltenyi Biotec cd66b ceacam8 granulocytes apc rea306 ud 130 117 692 miltenyi biotec cd68 macrosialin
    PGLYRP1, CAMP, MMP9, and <t>CEACAM8</t> mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.
    Cd66b Ceacam8 Granulocytes Apc Rea306 Ud 130 117 692 Miltenyi Biotec Cd68 Macrosialin, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/CD66b+Antibody%2C+anti-human%2C+REAfinity/pmc11247396__JEV2___13___e12456___s001-100-99-106
    Average 94 stars, based on 1 article reviews
    cd66b ceacam8 granulocytes apc rea306 ud 130 117 692 miltenyi biotec cd68 macrosialin - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ceacam8 origene rg204740 isotype mouseigg1 isotype control pe r d systems  (OriGene)
    90
    OriGene ceacam8 origene rg204740 isotype mouseigg1 isotype control pe r d systems
    PGLYRP1, CAMP, MMP9, and <t>CEACAM8</t> mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.
    Ceacam8 Origene Rg204740 Isotype Mouseigg1 Isotype Control Pe R D Systems, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/CD66b+(CEACAM8)+(NM_001816)+Human+Tagged+ORF+Clone/us11332528-390-112-113
    Average 90 stars, based on 1 article reviews
    ceacam8 origene rg204740 isotype mouseigg1 isotype control pe r d systems - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    ceacam8 cdna  (OriGene)
    90
    OriGene ceacam8 cdna
    PGLYRP1, CAMP, MMP9, and <t>CEACAM8</t> mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.
    Ceacam8 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/CD66b+(CEACAM8)+(NM_001816)+Human+Tagged+ORF+Clone/us11332528-390-109-113
    Average 90 stars, based on 1 article reviews
    ceacam8 cdna - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    ic002p anti ceacam8 antibody human ceacam8 pe conjugated r d systems fab4246p antibody  (R&D Systems)
    95
    R&D Systems ic002p anti ceacam8 antibody human ceacam8 pe conjugated r d systems fab4246p antibody
    PGLYRP1, CAMP, MMP9, and <t>CEACAM8</t> mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.
    Ic002p Anti Ceacam8 Antibody Human Ceacam8 Pe Conjugated R D Systems Fab4246p Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/Mouse+IgG1+PE-conjugated+Antibody/us11332528-390-121-119
    Average 95 stars, based on 1 article reviews
    ic002p anti ceacam8 antibody human ceacam8 pe conjugated r d systems fab4246p antibody - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    mouse anti human ceacam8 cd66b  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc mouse anti human ceacam8 cd66b
    PGLYRP1, CAMP, MMP9, and <t>CEACAM8</t> mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.
    Mouse Anti Human Ceacam8 Cd66b, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/GPX4+Antibody/pmc07591536__41467_2020_19193_MOESM3_ESM-46-113-112
    Average 97 stars, based on 1 article reviews
    mouse anti human ceacam8 cd66b - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    mouse anti human ceacam8 cd66b  (Novus Biologicals)
    90
    Novus Biologicals mouse anti human ceacam8 cd66b
    PGLYRP1, CAMP, MMP9, and <t>CEACAM8</t> mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.
    Mouse Anti Human Ceacam8 Cd66b, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ceacam8/Mouse+anti-Human+IgG2+Fc+Secondary+Antibody+(3C7)/pmc07591536-649-38-42
    Average 90 stars, based on 1 article reviews
    mouse anti human ceacam8 cd66b - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    PGLYRP1, CAMP, MMP9, and CEACAM8 mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.

    Journal: International Journal of Molecular Sciences

    Article Title: Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer

    doi: 10.3390/ijms25179735

    Figure Lengend Snippet: PGLYRP1, CAMP, MMP9, and CEACAM8 mRNA expression levels are increased in the blood of breast cancer patients treated with DOX-based chemotherapy after the 1st cycle (T1) of DOX-based chemotherapy in comparison with the baseline (T0). ( A ) Histogram showing the ΔCt values of PGLYRP1, CAMP, MMP9, and CEACAM8 in PBMCs of patients with cardiotoxicity (n = 16) and patients without cardiotoxicity (n = 16). Each dot represents one sample, and the mean ± SD for each group is indicated. ( B ) Fold change (2^-ΔΔCt) for each of the examined genes comparing T1 and T2, considering the T0 as a calibrator. ( C ) Receiver operating characteristic (ROC) curves for the ability of blood levels of the four mRNAs to predict DOX-induced cardiotoxicity in breast cancer. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8. p -value, * < 0.001, ** < 0.01, *** > 0.1.

    Article Snippet: We used the following ELISA kits and plasma dilutions: Human PGRPs/PGLYRP1 (Invitrogen# EHPGLYRP1, detection range: 6.14–1500 pg/mL, 1:100 diluted); Human CAMP/LL-37 (MyBioSource, # MBS167379, detection range 0.2–60 ng/mL, undiluted samples), Human CEACAM8/CD66B (MyBioSource, Cat# MBS2024215, detection range 15.62–1000 pg/mL, undiluted samples), Human MMP-9 (R and D Systems, #DMP900, detection range: 0.31–20 ng/mL, 1:100 diluted).

    Techniques: Expressing, Comparison

    Differences in the circulating protein biomarkers among patients with cardiotoxicity and no cardiotoxicity at baseline and after the first cycle of DOX-based chemotherapy.

    Journal: International Journal of Molecular Sciences

    Article Title: Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer

    doi: 10.3390/ijms25179735

    Figure Lengend Snippet: Differences in the circulating protein biomarkers among patients with cardiotoxicity and no cardiotoxicity at baseline and after the first cycle of DOX-based chemotherapy.

    Article Snippet: We used the following ELISA kits and plasma dilutions: Human PGRPs/PGLYRP1 (Invitrogen# EHPGLYRP1, detection range: 6.14–1500 pg/mL, 1:100 diluted); Human CAMP/LL-37 (MyBioSource, # MBS167379, detection range 0.2–60 ng/mL, undiluted samples), Human CEACAM8/CD66B (MyBioSource, Cat# MBS2024215, detection range 15.62–1000 pg/mL, undiluted samples), Human MMP-9 (R and D Systems, #DMP900, detection range: 0.31–20 ng/mL, 1:100 diluted).

    Techniques:

    Protein levels of PGLYRP1, CAMP, MMP9, and CEACAM8 are increased in the plasma of breast cancer patients after the 1st chemotherapy cycle and at >1 year after chemotherapy in comparison with the baseline. ( A ) Scatter plots demonstrating the comparison of the protein concentrations of the examined proteins in the plasma of breast cancer patients with cardiotoxicity (CTX) and non-cardiotoxicity (NCTX) at baseline (T0), after the first chemotherapy dose (T1), and at >1 year post treatment (T2). Each dot represents one sample, and the mean and SD for each group is indicated. ( B ) Protein expression levels of the examined markers in comparison with the cutoff values. ( C ) Receiver operating characteristic (ROC) curves for all examined neutrophil markers at CTX_T1 versus HC + NCTX_T0 + CT_T0. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8. AUC = area under the curve. p -Value, * < 0.05, ** > 0.01.

    Journal: International Journal of Molecular Sciences

    Article Title: Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer

    doi: 10.3390/ijms25179735

    Figure Lengend Snippet: Protein levels of PGLYRP1, CAMP, MMP9, and CEACAM8 are increased in the plasma of breast cancer patients after the 1st chemotherapy cycle and at >1 year after chemotherapy in comparison with the baseline. ( A ) Scatter plots demonstrating the comparison of the protein concentrations of the examined proteins in the plasma of breast cancer patients with cardiotoxicity (CTX) and non-cardiotoxicity (NCTX) at baseline (T0), after the first chemotherapy dose (T1), and at >1 year post treatment (T2). Each dot represents one sample, and the mean and SD for each group is indicated. ( B ) Protein expression levels of the examined markers in comparison with the cutoff values. ( C ) Receiver operating characteristic (ROC) curves for all examined neutrophil markers at CTX_T1 versus HC + NCTX_T0 + CT_T0. NCTX, non-cardiotoxicity; CTX, cardiotoxicity; PGLYRP1, peptidoglycan recognition protein 1; CAMP, cathelicidin antimicrobial peptide; MMP9, matrix metallopeptidase; CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8. AUC = area under the curve. p -Value, * < 0.05, ** > 0.01.

    Article Snippet: We used the following ELISA kits and plasma dilutions: Human PGRPs/PGLYRP1 (Invitrogen# EHPGLYRP1, detection range: 6.14–1500 pg/mL, 1:100 diluted); Human CAMP/LL-37 (MyBioSource, # MBS167379, detection range 0.2–60 ng/mL, undiluted samples), Human CEACAM8/CD66B (MyBioSource, Cat# MBS2024215, detection range 15.62–1000 pg/mL, undiluted samples), Human MMP-9 (R and D Systems, #DMP900, detection range: 0.31–20 ng/mL, 1:100 diluted).

    Techniques: Comparison, Expressing

    Comparison between the means of after–before (T1-T0) and (T2-T0) DOX-based chemotherapy differences in the two groups of breast cancer patients, the group with cardiotoxicity (CTX) and the group with no cardiotoxicity (NCTX).

    Journal: International Journal of Molecular Sciences

    Article Title: Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer

    doi: 10.3390/ijms25179735

    Figure Lengend Snippet: Comparison between the means of after–before (T1-T0) and (T2-T0) DOX-based chemotherapy differences in the two groups of breast cancer patients, the group with cardiotoxicity (CTX) and the group with no cardiotoxicity (NCTX).

    Article Snippet: We used the following ELISA kits and plasma dilutions: Human PGRPs/PGLYRP1 (Invitrogen# EHPGLYRP1, detection range: 6.14–1500 pg/mL, 1:100 diluted); Human CAMP/LL-37 (MyBioSource, # MBS167379, detection range 0.2–60 ng/mL, undiluted samples), Human CEACAM8/CD66B (MyBioSource, Cat# MBS2024215, detection range 15.62–1000 pg/mL, undiluted samples), Human MMP-9 (R and D Systems, #DMP900, detection range: 0.31–20 ng/mL, 1:100 diluted).

    Techniques: Comparison